Editorial Material
Immunology
Pin Li, Napoleone Ferrara
Summary: This study reveals the crosstalk between VEGF receptors in different organs and emphasizes the importance of VEGF receptor expression and interplay in vascular heterogeneity.
JOURNAL OF EXPERIMENTAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Yusuke Masuo, Ken-ichi Fujita, Kazuhiro Shimada, Noriho Iida, Tomohiko Wakayama, Yukio Kato, Aya Hasan Alshammari
Summary: This study explains the occurrence of hand-foot skin reaction (HFSR) in patients treated with tyrosine kinase inhibitors (TKIs) by examining keratinocyte toxicity and VEGFR-2 inhibition.
BIOCHEMICAL PHARMACOLOGY
(2022)
Review
Peripheral Vascular Disease
Ferdinand A. C. le Noble, Jean-Jacques Mourad, Bernard I. Levy, Harry A. J. Struijker-Boudier
Summary: Drugs inhibiting VEGF have been widely used in cancer treatment, but they often cause cardiovascular side effects, with hypertension being the most frequently observed. This review explores the mechanism behind VEGF inhibitor-induced hypertension, focusing on microvascular rarefaction, which is supported by evidence from experimental and clinical studies.
Article
Pharmacology & Pharmacy
Caiyun Nie, Weifeng Xu, Huifang Lv, Xiaohui Gao, Guofeng Li, Beibei Chen, Jianzheng Wang, Yingjun Liu, Jing Zhao, Yunduan He, Saiqi Wang, Xiaobing Chen
Summary: This study evaluated the clinical efficacy and safety of different treatment strategies for patients with advanced or metastatic gastric cancer. The results showed that anti-angiogenic TKIs plus chemotherapy demonstrated superior therapeutic efficacy compared to chemotherapy alone, while TKIs + ICIs did not show a clinical advantage over chemotherapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Alessandro Comandone, Federica Vana, Tiziana Comandone, Marcello Tucci
Summary: In recent years, research on the biological mechanisms and treatment of clear cell renal carcinoma has made significant progress. Neo-angiogenesis has been identified as a key player in tumor growth and metastasis, leading to the approval of antiangiogenic drugs with impressive results in treatment outcomes.
Article
Chemistry, Medicinal
Sung Min Cho, Yonghyo Kim, Yooju Jung, Minjeong Ko, Gyorgy Marko-Varga, Ho Jeong Kwon
Summary: A novel natural small molecule, voacangine (Voa), has been discovered as a potent antiangiogenic compound that directly binds to and inhibits the kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2). Synthetic molecules based on Voa's chemical structure, such as Voa analogue 19 (V19), show increased antiangiogenic potency without cytotoxic effects and induce significant tumor cell death in a mouse xenograft model. This VEGFR2 modulator, inspired by the natural compound Voa's rigid scaffold, presents a promising candidate for development of new antiangiogenic agents.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Oncology
Giandomenico Roviello, Elisabetta Gambale, Roberta Giorgione, Daniele Santini, Marco Stellato, Giuseppe Fornarini, Sara Elena Rebuzzi, Umberto Basso, Davide Bimbatti, Laura Doni, Gabriella Nesi, Melissa Bersanelli, Sebastiano Buti, Ugo De Giorgi, Luca Galli, Andrea Sbrana, Raffaele Conca, Claudia Carella, Emanuele Naglieri, Sandro Pignata, Giuseppe Procopio, Lorenzo Antonuzzo
Summary: This study aimed to compare the survival outcomes between active treatment and best supportive care (BSC) in patients who failed on nivolumab and cabozantinib therapies. The results showed that patients on active treatment had significantly longer overall survival compared to those on BSC.
Review
Oncology
Hana Studentova, Martina Spisarova, Andrea Kopova, Anezka Zemankova, Bohuslav Melichar, Vladimir Student
Summary: Cytoreductive nephrectomy has long been considered the standard of care for patients with metastatic renal cell carcinoma. However, with the rapid changes in systemic therapy, the importance of this procedure has been widely discussed and disputed. Currently, there is a lack of prospective data on cytoreductive nephrectomy in the immunotherapy era, and retrospective studies with small patient numbers are the main source of evidence. Nevertheless, an individualized approach can help identify patients who may benefit from surgery combined with systemic treatment.
Review
Biochemistry & Molecular Biology
Manali Tilak, Jennifer Holborn, Laura A. New, Jasmin Lalonde, Nina Jones
Summary: Glioblastoma multiforme (GBM) is a deadly cancer with limited response to existing therapies. Subtypes of GBM with distinct genetic signatures show aberrant activation of signal transduction pathways. Current research focuses on understanding these molecular alterations to develop more efficient targeted therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Pharmacology & Pharmacy
Martina Catalano, Giuseppe Procopio, Pierangela Sepe, Matteo Santoni, Francesco Sessa, Donata Villari, Gabriella Nesi, Giandomenico Roviello
Summary: In the past decade, the management of metastatic renal cell carcinoma (RCC) has greatly improved with frontline immunotherapy, particularly the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). While this combination is considered the preferred treatment for all metastatic RCC patients, concerns have been raised regarding its efficacy in patients with favorable risk scores. This review aims to explain the rationale behind TKI and ICI combination therapies, summarize the current approved first-line combinations for metastatic RCC, and discuss the challenges and future directions in this field.
PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Eva Juengel, Pascal Schnalke, Jochen Rutz, Sebastian Maxeiner, Felix K. -H. Chun, Roman A. Blaheta
Summary: Axitinib significantly suppressed the growth of sunitinib-resistant HUVECs and induced cell cycle arrest at the G0/G1 phase. Both axitinib and sorafenib reduced HUVEC tube length and prevented wound closure in sunitinib-resistant HUVECs after six weeks of treatment, with sorafenib showing slightly better results.
Review
Immunology
Yue Chen, Haoyue Hu, Xianglei Yuan, Xue Fan, Chengda Zhang
Summary: Hepatocellular carcinoma (HCC) is a challenging cancer to treat, but the application of immune checkpoint inhibitors (ICIs) has brought new hope. Combination therapies involving antiangiogenic drugs and ICIs or two ICIs may have a synergistic action and have shown greater efficacy in advanced HCC.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Kinga Krawczyk, Katarzyna Sladowska, Przemyslaw Holko, Pawel Kawalec
Summary: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs) used as monotherapy or combination therapy for the first-line treatment of metastatic clear cell RCC. The results showed that sorafenib and tivozanib used as monotherapy were the best treatment options, while the safety profile was poorer when TKIs were used in combination with immunological agents.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Lihua Sun, Hui Tian, Songguo Xue, Hongjuan Ye, Xue Xue, Rongxiang Wang, Yu Liu, Caixia Zhang, Qiuju Chen, Shaorong Gao
Summary: A hormone-sensitive signaling pathway in ovarian cells has been identified as a potential target for better treatment of infertility-associated complications. The study found a strong connection between the exposure to human chorionic gonadotropin (hCG) and the expression of a signaling protein associated with blood vessels in ovarian cells, offering new insights into the prevention and management of ovarian hyperstimulation syndrome (OHSS).
EXPERIMENTAL AND MOLECULAR MEDICINE
(2022)
Review
Oncology
Joseph A. Vento, Brian Rini
Summary: The treatment of refractory renal cell carcinoma is constantly evolving. Combination therapies of immune checkpoint inhibitors and targeted tyrosine kinase inhibitors have shown improvement in first-line treatment. However, some patients do not respond to these treatments, necessitating the search for effective options. This review explores the current treatment options, ongoing trials, and considerations for non-clear cell histologies in refractory renal cell carcinoma.
